NRx Pharmaceuticals: Funding, Investors & Team (Oct 2026)
NRx Pharmaceuticals is a clinical-stage pharmaceutical company developing therapeutics for the treatment of central nervous system disorders and pulmonary diseases. It addresses life-threatening diseases that often go untreated by researching, developing, and scaling solutions to help people who most desperately need them. The company has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure, and is also developing NRX-100/101 which is the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior. In July 2021, the Government of Israel awarded NRx the exclusive worldwide right to develop and market the BriLifeR COVID vaccine developed by the Israel Institute for Biological Research.
NRx Pharmaceuticals has raised $93.5M across 8 funding rounds on record, the most recent an undisclosed round of $22.3M announced in Jun 2026.
That round is above the $8.1M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
NRx Pharmaceuticals Company Profile and Key Stats
Latest funding round on record: Jun 2026.
NRx Pharmaceuticals Funding Rounds
NRx Pharmaceuticals raised $30.0M in a Post-IPO Equity announced in Aug 2021.
1.3 years later, an undisclosed round of $11.0M was announced in Nov 2022.
4 months later, an undisclosed round of $2.9M was announced in Mar 2023.
3 months later, an undisclosed round of $6.3M was announced in Jun 2023.
8 months later, an undisclosed round of $1.5M was announced in Feb 2024.
6 months later, an undisclosed round of $16.0M was announced in Aug 2024.
5 months later, an undisclosed round of $3.5M was announced in Jan 2025.
1.4 years later, an undisclosed round of $22.3M was announced in Jun 2026.
NRx Pharmaceuticals Founders and Leadership Team
Contact details for the NRx Pharmaceuticals team: 1 of 4 have an email address on file.
Start 14-day free trial →NRx Pharmaceuticals Funding Compared to Other Biotechnology Startups
NRx Pharmaceuticals' latest round of $22.3M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like NRx Pharmaceuticals in Biotechnology and Wilmington
Companies Similar to NRx Pharmaceuticals
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Circle Pharma is a biotechnology company in the initial stages of development that uses unique computational…
Evvy is for people with vaginas who want to be empowered with information about their microbiome. Their…
NRx Pharmaceuticals Funding FAQs
What does NRx Pharmaceuticals do?
NRx Pharmaceuticals is a clinical-stage pharmaceutical company developing therapeutics for the treatment of central nervous system disorders and pulmonary diseases. It addresses life-threatening diseases that often go untreated by researching, developing, and scaling solutions to help people who most desperately need them. The company has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure, and is also developing NRX-100/101 which is the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior. In July 2021, the Government of Israel awarded NRx the exclusive worldwide right to develop and market the BriLifeR COVID vaccine developed by the Israel Institute for Biological Research.
How much funding has NRx Pharmaceuticals raised?
NRx Pharmaceuticals has raised $93.5M across 8 rounds on record. The most recent is an undisclosed round of $22.3M announced in Jun 2026.
When did NRx Pharmaceuticals last raise funding?
NRx Pharmaceuticals' most recent funding round on record is an undisclosed round of $22.3M, announced in Jun 2026.
Who founded NRx Pharmaceuticals?
FundedIQ lists Jonathan C (Founder), Jonathan C Javitt (Founder), Jonathan C. Javitt (Founder) at NRx Pharmaceuticals.
Who is the CEO of NRx Pharmaceuticals?
Jonathan Javitt is listed as CEO at NRx Pharmaceuticals.
Where is NRx Pharmaceuticals headquartered?
NRx Pharmaceuticals is based in Wilmington, Delaware, United States.
How many employees does NRx Pharmaceuticals have?
NRx Pharmaceuticals is in the 11-50 employee band.
How does NRx Pharmaceuticals' funding compare to other Biotechnology startups?
NRx Pharmaceuticals' latest round of $22.3M is above the $8.1M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's NRx Pharmaceuticals Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for NRx Pharmaceuticals is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.